Difference between revisions of "Team:UI Indonesia/Safety"

 
(15 intermediate revisions by 5 users not shown)
Line 259: Line 259:
 
         </li>
 
         </li>
 
         <li class="navbar-parts"><a href="https://2018.igem.org/Team:UI_Indonesia/Parts">Parts</a></li>
 
         <li class="navbar-parts"><a href="https://2018.igem.org/Team:UI_Indonesia/Parts">Parts</a></li>
−
<li class="navbar-safety current"><a href="https://2018.igem.org/Team:UI_Indonesia/Safety">Safety</a></li>
+
    <li class="navbar-safety current"><a href="https://2018.igem.org/Team:UI_Indonesia/Safety">Safety</a></li>
−
<li class="dropdown navbar-interlab">
+
    <li class="dropdown navbar-interlab">
 
           <a href="https://2018.igem.org/Team:UI_Indonesia/InterLab">InterLab<span class="caret"></span></a>
 
           <a href="https://2018.igem.org/Team:UI_Indonesia/InterLab">InterLab<span class="caret"></span></a>
 
           <ul class="dropdown-menu">
 
           <ul class="dropdown-menu">
Line 266: Line 266:
 
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#materials">Materials and Equipment</a></li>
 
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#materials">Materials and Equipment</a></li>
 
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#methods">Methods</a></li>
 
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#methods">Methods</a></li>
−
<li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#results">Results and Discussions</a></li>
+
      <li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#results">Results and Discussions</a></li>
−
<li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#conclusions">Conclusions</a></li>
+
      <li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#conclusions">Conclusions</a></li>
 
           </ul>
 
           </ul>
 
         </li>
 
         </li>
−
<li class="navbar-model"><a href="https://2018.igem.org/Team:UI_Indonesia/Model">Model</a></li>
+
    <li class="navbar-model"><a href="https://2018.igem.org/Team:UI_Indonesia/Model">Model</a></li>
−
<li class="dropdown navbar-humanpractice">
+
    <li class="dropdown navbar-humanpractice">
−
           <a href="https://2018.igem.org/Team:UI_Indonesia/HumanPractices">Human Practices<span class="caret"></span></a>
+
           <a href="https://2018.igem.org/Team:UI_Indonesia/Human_Practices">Human Practices<span class="caret"></span></a>
 
           <ul class="dropdown-menu">
 
           <ul class="dropdown-menu">
−
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/HumanPractices#collapse1">Campus Campaign</a></li>
+
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/Human_Practices">Integrated Human Practice</a></li>
−
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/HumanPractices#collapse2">Social Work</a></li>
+
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/Public_Engagement">Education and Public Engagement</a></li>
−
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/HumanPractices#collapse3">Biosafety & Biosecurity Training</a></li>
+
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/Human_Practices#catalogue">Human Practice Catalogue</a></li>
−
<li><a href="https://2018.igem.org/Team:UI_Indonesia/HumanPractices#collapse4">Human Practice Catalogue</a></li>
+
          </ul>
 +
    </li>
 +
    <li class="navbar-improve"><a href="https://2018.igem.org/Team:UI_Indonesia/Improve">Improve</a></li>
 +
    <li class="navbar-team"><a href="https://2018.igem.org/Team:UI_Indonesia/Team">Team</a></li>
 +
    <li class="navbar-collaborations"><a href="https://2018.igem.org/Team:UI_Indonesia/Collaborations">Collaborations</a></li>
 +
        <li class="dropdown navbar-attributions">
 +
          <a href="https://2018.igem.org/Team:UI_Indonesia/Attributions">Attributions<span class="caret"></span></a>
 +
          <ul class="dropdown-menu">
 +
            <li><a href="https://2018.igem.org/Team:UI_Indonesia/MedalCriteria">Medal Criteria</a></li>
 
           </ul>
 
           </ul>
 
         </li>
 
         </li>
−
<li class="navbar-improve"><a href="https://2018.igem.org/Team:UI_Indonesia/Improve">Improve</a></li>
 
−
<li class="navbar-team"><a href="https://2018.igem.org/Team:UI_Indonesia/Team">Team</a></li>
 
−
<li class="navbar-collaborations"><a href="https://2018.igem.org/Team:UI_Indonesia/Collaborations">Collaborations</a></li>
 
−
<li class="navbar-attributions"><a href="https://2018.igem.org/Team:UI_Indonesia/Attributions">Attributions</a></li>
 
 
       </ul>
 
       </ul>
 
     </div>
 
     </div>
Line 298: Line 302:
  
 
<div class="w3-content w3-container w3-padding-64">
 
<div class="w3-content w3-container w3-padding-64">
−
  <h5> One of our part which raised concern about security is the DiphTox part. The details regarding this part is discussed in <b><a  href ="http://parts.igem.org/Part:BBa_K2607000">the following page</a></b> (http://parts.igem.org/Part:BBa_K2607000). The fact that this part originates from the modification of diphtheria toxin raises concern about safety and security, including the possibility of dual-use. Regarding safety issues, one of the main purposes of the creation of this part is to eliminate the toxic domain of the protein, leaving only the binding domain to be used as test device for HB-EGF/Tar chimeric receptor. However, this still leaves a security issue regarding dual-use possibilities. The creation of this part, if successful, are meant to be used solely as test device. In handling this condition, we applied to the safety committee to be allowed to not publish its full sequence in iGEM UI 2018 wiki. We have also discussed this matter with our PI, dr. Budiman Bela, and also with the Lab Biosafety Officer, Mrs. Aroem Naroeni, which also shared the safety aspects of our laboratory.
+
<h5>In accordance to the iGEM safety rules, our team used organism classified in the Risk Group 1, such as Escherichia coli K-12-strain derivates. To ensure the safety of ourselves and the project, our lab team worked in a BSL-1 (Biosafety Level 1) laboratory, certified internationally by WHO and CEN, in the Institute of Human Virology and Cancer Biology of the Faculty of Medicine, University of Indonesia. The safety criteria of this lab include risk assessment for each project, safety trainings, and standard operational procedures. Several lab administrative strategies are available such as medical surveillance and vaccination for those working with potentially infected human tissues, accident report, and safety drills.</h5> 
 +
<br>
 +
<div align = "center">
 +
<img src = "https://static.igem.org/mediawiki/2018/6/62/T--UI_Indonesia--genlab.png"</img>
 +
</div>
 +
<br>
 +
 
 +
<h5> One of our part which raised concern about security is the DiphTox part. The details regarding this part is discussed in <a  href ="http://parts.igem.org/Part:BBa_K2607000" style="color:blue">http://parts.igem.org/Part:BBa_K2607000</a> Regarding safety issues, one of the main purposes of the creation of this part is to eliminate the toxic domain of the protein, leaving only the binding domain to be used as test device for HB-EGF/Tar chimeric receptor. In managing the data, our laboratory had applied several safeguards, such as restricted informational access or password-locked computer. We have also discussed this matter with our PI, dr. Budiman Bela, and also with the Lab Biosafety Officer, Mrs. Aroem Naroeni, which also shared the safety aspects of our laboratory.</h5>
  
 
<br>
 
<br>
−
<img src = "https://static.igem.org/mediawiki/2018/8/8d/T--UI_Indonesia--safety1.jpg" ></img>
+
<img src = "https://static.igem.org/mediawiki/2018/8/8d/T--UI_Indonesia--safety1.jpg" width="700"></img>
 
<h6 align ="center"><b>Figure 1</b>. One of our lab member (<i>Left</i>) interviews Mrs. Aroem (<i>Right</i>) for asking any advices and suggestions regarding team’s project and lab safety.</h5>
 
<h6 align ="center"><b>Figure 1</b>. One of our lab member (<i>Left</i>) interviews Mrs. Aroem (<i>Right</i>) for asking any advices and suggestions regarding team’s project and lab safety.</h5>
−
  <br><br>
 
−
 
 
−
  The dual-use potential of our part meant that the sequence became a sensitive data. In managing sensitive data, our laboratory had applied several safeguards. It begins with logbooks which by the end of the project will be locked up and access will be limited. Other sensitive data, including viral genome sequences, are locked up in a password-protected computer. Anyone requesting access would only be given necessarily after signing an agreement to protect secrecy and by the end of their project, the exit clearance procedure requires the handling of all data to the lab. How much data will be published is a matter to be discussed together with the authorities of the laboratory.
 
−
 
 
<br><br>
 
<br><br>
  
−
As a part of the development of biosafety and biosecurity, iGEM UI team had recently been given the chance to be a speaker in a training conducted by the Indonesian Biorisk Association together with the Federal Bureau Interagency, regarding the potential of dual-use in our project. We planned to consult with the FBI experts about future usage of DiphTox part in this seminar by the end of October 2018.
+
<h5>As a part of the development of biosafety and biosecurity, iGEM UI team had recently been given the chance to be a speaker in a training conducted by the Indonesian Biorisk Association together with the Federal Bureau Interagency, regarding the potential of dual-use in our project. We planned to consult with the FBI experts about future usage of DiphTox part in this seminar by the end of October 2018.</h5>
  
 
</h5>
 
</h5>

Latest revision as of 03:42, 18 October 2018

SAFETY AND SECURITY ASPECTS
In accordance to the iGEM safety rules, our team used organism classified in the Risk Group 1, such as Escherichia coli K-12-strain derivates. To ensure the safety of ourselves and the project, our lab team worked in a BSL-1 (Biosafety Level 1) laboratory, certified internationally by WHO and CEN, in the Institute of Human Virology and Cancer Biology of the Faculty of Medicine, University of Indonesia. The safety criteria of this lab include risk assessment for each project, safety trainings, and standard operational procedures. Several lab administrative strategies are available such as medical surveillance and vaccination for those working with potentially infected human tissues, accident report, and safety drills.


One of our part which raised concern about security is the DiphTox part. The details regarding this part is discussed in http://parts.igem.org/Part:BBa_K2607000 Regarding safety issues, one of the main purposes of the creation of this part is to eliminate the toxic domain of the protein, leaving only the binding domain to be used as test device for HB-EGF/Tar chimeric receptor. In managing the data, our laboratory had applied several safeguards, such as restricted informational access or password-locked computer. We have also discussed this matter with our PI, dr. Budiman Bela, and also with the Lab Biosafety Officer, Mrs. Aroem Naroeni, which also shared the safety aspects of our laboratory.

Figure 1. One of our lab member (Left) interviews Mrs. Aroem (Right) for asking any advices and suggestions regarding team’s project and lab safety.


As a part of the development of biosafety and biosecurity, iGEM UI team had recently been given the chance to be a speaker in a training conducted by the Indonesian Biorisk Association together with the Federal Bureau Interagency, regarding the potential of dual-use in our project. We planned to consult with the FBI experts about future usage of DiphTox part in this seminar by the end of October 2018.
Team UI Indonesia
  igemui2018@gmail.com